Endonovo Therapeutics, Inc. (ENDV)

Market Cap	180.76K +49.8%
Revenue (ttm)	255.72K +1,699.9%
Net Income	-4.40M
EPS	-0.06
Shares Out	1.81B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.000001 - 0.0002
Beta	38.48
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Endonovo Therapeutics

Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardio chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular, and periph...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: ENDV

Financial Performance

In 2022, Endonovo Therapeutics's revenue was $135,355, an increase of 85.15% compared to the previous year's $73,105. Losses were -$18.47 million, 495.0% more than in 2021.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 8, 2026

Data Sources Report a data error